Kennedy Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.7M Buy
361,556
+19,228
+6% +$735K 0.22% 158
2026
Q2
$12.7M Sell
342,328
-9,974
-3% -$322K 0.23% 161
2026
Q1
$11.2M Buy
+352,302
New +$9.6M 0.24% 157
2024
Q2
– Sell
-33,586
Closed -$1.41M – 710
2024
Q1
$1.41M Sell
33,586
-28,586
-46% -$1.17M 0.03% 581
2023
Q4
$2.47M Sell
62,172
-25,222
-29% -$742K 0.05% 451
2023
Q3
$2.41M Buy
87,394
+166
+0.2% +$5.2K 0.06% 421
2023
Q2
$2.96M Buy
87,228
+5,862
+7% +$198K 0.07% 396
2023
Q1
$2.93M Buy
81,366
+47
+0.1% +$2.03K 0.09% 352
2022
Q4
$3.62M Sell
81,319
-31
-0% -$1.11K 0.1% 334
2022
Q3
$2.29M Buy
81,350
+57,034
+235% +$1.75M 0.07% 395
2022
Q2
$656K Sell
24,316
-201
-0.8% -$5.84K 0.02% 519
2022
Q1
$835K Sell
24,517
-3,641
-13% -$116K 0.02% 517
2021
Q4
$1.09M Buy
+28,158
New +$1.23M 0.02% 506

Other funds holding CLDX

Kennedy Capital Management's CLDX Position: Q3 2026 in Review

Kennedy Capital Management increased its Celldex Therapeutics (CLDX) stake by 5.6% in Q3 2026, buying an estimated $735K and bringing the position to 361,556 shares worth $11.7M. The position accounts for 0.22% of the portfolio, ranked #158.

Kennedy Capital Management first reported a position in CLDX in Q4 2021 and has held it in 13 quarters since. The position peaked at $12.7M in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Kennedy Capital Management held 361,556 shares of Celldex Therapeutics worth $11.7M as of Q3 2026.
  • Kennedy Capital Management bought 19,228 Celldex Therapeutics shares in Q3 2026, an estimated $735K.
  • Celldex Therapeutics made up 0.22% of Kennedy Capital Management's portfolio in Q3 2026, its #158 holding.
  • Kennedy Capital Management first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Kennedy Capital Management's Celldex Therapeutics position peaked at $12.7M in Q2 2026.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.